A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors Meeting Abstract
| Authors: | Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A.; Garofalo, A.; Akella, L. V.; Yu, Z.; Nguyen, M. H.; Orford, K. W.; Klempner, S. J. |
| Abstract Title: | A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.TPS3169 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS3169 -- Source: Cinahl |
